LOXO 783
Alternative Names: LOX-22783; LOXO-783; LY-3849524Latest Information Update: 31 Oct 2023
At a glance
- Originator Loxo Oncology
- Class Antineoplastics
- Mechanism of Action 3-phosphoinositide-dependent protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Solid tumours
Most Recent Events
- 23 Oct 2023 Loxo Oncology plans a phase I pharmacokinetics trial for LOXO 783 (In volunteers) in USA (PO) (NCT06102512) in October 2023
- 02 Aug 2023 Eli Lily and company and Loxo Oncology initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT06028425)
- 09 Jul 2023 Eli Lilly and Company completes a phase I pharmacokinetics trial for Healthy volunteers in USA (PO)(NCT05894928)